Percheron Therapeutics Ltd News

Percheron Therapeutics Ltd: Deborah Ambrosini appointed as CFO & Company Secretary

Jun 17 07:04

Percheron Therapeutics Ltd: Percheron appoints Dr Cathryn Clary as Chief Medical Advisor

Jun 3 06:31

Percheron Therapeutics Ltd: Percheron to present at 2024 BIO International Convention

May 31 06:32

Percheron Therapeutics Ltd: Phase IIb study of ATL1102 in DMD completes recruitment

May 29 07:01

Percheron Therapeutics Ltd: Preliminary Results of 9 Month Toxicology Study of ATL1102

May 27 07:41

Percheron Therapeutics Ltd: US Patent Granted for ATL1102 in Duchenne muscular dystrophy

May 20 06:41

Percheron Therapeutics Ltd: WHO selects proposed INN for ATL1102

May 6 06:52

Percheron Therapeutics Ltd: Quarterly Activities/Appendix 4C Cash Flow Report

Apr 30 06:53

Percheron Therapeutics Ltd: Change in substantial holding

Apr 26 14:59

Percheron Therapeutics Ltd: ATL1102 Clinical Trial Update

Apr 2 06:07

Percheron Therapeutics Ltd: ATL1102 Data presented at MDA Annual Conference

Mar 4 05:49

Percheron Therapeutics Ltd: Half Yearly Report and Accounts

Feb 28 14:20

Percheron Therapeutics Ltd: Percheron Therapeutics Limited Corporate Presentation

Feb 26 05:27

Percheron Therapeutics Ltd: Change of Registered Office and Principal Place of Business

Feb 21 05:22

Percheron Therapeutics Ltd: Receipt of R&D Tax incentive payment

Feb 12 05:39

Percheron Therapeutics Ltd: Quarterly Activities/Appendix 4C Cash Flow Report

Jan 31 06:12

Percheron Therapeutics Ltd: ATL1102 DMD Phase IIA Final Data Published

Jan 29 05:28